10X Genomics is a health information services business based in the US. 10X Genomics shares (TXG) are listed on the NASDAQ and all prices are listed in US Dollars. 10X Genomics employs 1,259 staff and has a trailing 12-month revenue of around $625.4 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $18.97 |
|---|---|
| 52-week range | $15.28 - $63.57 |
| 50-day moving average | $21.23 |
| 200-day moving average | $36.41 |
| Wall St. target price | $30.86 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.24 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $18.97 from 2024-07-24
| 1 week (2024-07-18) | 14.55% |
|---|---|
| 1 month (2024-06-25) | -3.16% |
| 3 months (2024-04-25) | -29.48% |
| 6 months (2024-01-25) | -55.26% |
| 1 year (2023-07-25) | -68.83% |
|---|---|
| 2 years (2022-07-25) | -46.44% |
| 3 years (2021-07-23) | 183.47 |
| 5 years (2019-07-21) | N/A |
| Revenue TTM | $625.4 million |
|---|---|
| Gross profit TTM | $396 million |
| Return on assets TTM | -13.06% |
| Return on equity TTM | -34.75% |
| Profit margin | -42.26% |
| Book value | $6.01 |
| Market Capitalization | $2 billion |
TTM: trailing 12 months
We're not expecting 10X Genomics to pay a dividend over the next 12 months.
10X Genomics's shares were split on a 1:2 basis on 16 July 2006. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your 10X Genomics shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for 10X Genomics shares which in turn could have impacted 10X Genomics's share price.
Over the last 12 months, 10X Genomics's shares have ranged in value from as little as $15.28 up to $63.57. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while 10X Genomics's is 1.841. This would suggest that 10X Genomics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
10x Genomics, Inc. , a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc.
Steps to owning and managing ZTEK, with 24-hour and historical pricing before you buy.
Steps to owning and managing MYNZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing ATAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing OWLT, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing HUM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ILMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.